top of page
News & Publications
Matrivax’ CSO Kevin Killeen Discusses MVX01 and Pneumococcal Vaccination during the World Immunization Week
Hear the podcast here in which Matrivax’ CSO talks about pneumococcal disease vaccination, our lead vaccine MVX01 and the start of our Phase 1 clinical study. The podcast aired to millions of listeners on multiple media outlets in the UK.
April 30, 2023
Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid
Thanawastien A, Joyce KE, Cartee RT, Haines, LA, Pelton SI, Tweten RK, Killeen KP. Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid. Vaccine 2021; 39(11):1652-1660.
Online 2020: https://doi.org/10.1016/j.vaccine.2020.04.064 2020
bottom of page